Cramer Backs UnitedHealth and CVS Over Clover Health Despite CLOV Gains
Jim Cramer called Clover Health a solid speculative bet but maintained that UnitedHealth and CVS remain his top healthcare picks.
CNBC's Jim Cramer acknowledged Clover Health (CLOV) as a worthwhile speculative play for risk-tolerant investors, but stopped short of elevating the smaller insurer above the established giants he continues to favor — UnitedHealth Group and CVS Health.
Cramer's commentary highlights a broader tension in the healthcare sector between high-risk, high-reward smaller operators like Clover and the blue-chip stability offered by UnitedHealth and CVS. While speculative names can generate outsized short-term returns, veteran analysts and market commentators have long cautioned that durability and earnings consistency matter more over a full market cycle.
Read more Ranking the Magnificent Seven Stocks by Future Cash Flow Value →
Clover Health has attracted attention from retail investors drawn to its technology-driven approach to Medicare Advantage insurance, but the company has faced persistent profitability questions since its 2021 SPAC debut. UnitedHealth and CVS, by contrast, carry diversified revenue streams — from pharmacy benefits management to direct care delivery — that provide a measure of insulation against regulatory and reimbursement headwinds.
Cramer's preference for the two larger names reflects a risk-management posture familiar to many institutional investors: acknowledge speculative upside where it exists, but anchor a portfolio in companies with proven cash flow and scale. For retail investors watching the healthcare space, the distinction between a trade and a long-term holding has rarely been more relevant given ongoing uncertainty around Medicare policy and drug pricing reform.
Continue reading at Yahoo Finance.
